chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually has chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable and treatable disease.

Chronic%20obstructive%20pulmonary%20disease Patient Education

Patient Education

  • It plays an important role in the following:
  • Increasing patient’s knowledge and understanding of the disease
  • Improving skills in symptom recognition, breathing and physical exercise, medication use including proper technique and environmental modification
    • Important to note that adherence to inhaled medications has been associated with reduced risk of death and hospital admission due to COPD exacerbations
    • Measures must be taken to reduce total personal exposure to tobacco smoke, occupational dusts and chemicals and air pollutants
  • Improving attitude toward nutrition and exercise, smoking cessation, quality of life factors and coping skills (eg relaxation techniques, stress management)
  • Improving patient responses to exacerbations
  • Initiating discussions about end-of-life issues including advance directives

Lifestyle Modification

Smoking Cessation

  • The single most effective and cost effective method to reduce the risk of developing COPD and to stop its progression
    • Counseling may be employed to aid patient
    • Pharmacotherapies to aid smoking cessation eg Nicotine preparations, Bupropion, Nortriptyline and Varenicline may be considered (Please see Smoking Cessation disease management chart for further information)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 18 Sep 2020
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, 2 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.